Sex: F
Vaccine: COVID19
Symptoms: Uveitis, Visual acuity tests
Clinical narrative: Acute panuveitis after COVID-19 mRNA booster vaccination; Initially this case has been considered invalid as ICH-unidentifiable patients.  This is a literature report for the following literature source(s): "Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery".  A 68-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "blunt force trauma" (unspecified if ongoing); "perinephric abscess" (unspecified if ongoing); "mild myopic refractive error" (unspecified if ongoing); "nephrectomy" (unspecified if ongoing); "cataract surgery" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunisation; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 immunisation. The following information was reported: UVEITIS (prolonged hospitalization, medically significant), outcome "recovered", described as "Acute panuveitis after COVID-19 mRNA booster vaccination". The patient underwent the following laboratory tests and procedures: C-reactive protein: Negative; Culture: negative; negative; Fundus autofluorescence: was significant for mild asymmetry of the cup to, notes: was significant for mild asymmetry of the cup to disc ratio at 0.4 and 0.6 for the right and left eyes; Gram stain: negative; Intraocular pressure test: 23 mmHg; 18 mmHg; normal; normal; Nucleic acid test: negative; Polymerase chain reaction: negative; Red blood cell sedimentation rate: Negative; Slit-lamp examination: was significant for 3 (plus) cortical, 2 (plus) nu, notes: was significant for 3 (plus) cortical, 2 (plus) nuclear sclerotic, and 1 (plus) posterior subcapsular cataracts in both eyes; significant for 2 (plus)  conjunctival injection,, notes: significant for 2 (plus)  conjunctival injection, mild stromal edema, 4(plus) cell and flare with trace hypopyon, and 4 (plus) anterior vitreous cell without any wound leak; improved to (plus) injection, (plus) punctate epit, notes: improved to (plus) injection, (plus) punctate epithelial erosions, 1-2 (plus) Descemet folds, 2 (plus) mixed cells in the AC without hypopyon or fibrin, and 2(plus) vitreous cell; Ultrasound eye: demonstrates an attached retina and the presence, notes: demonstrates an attached retina and the presence of dense vitreous cell; Visual acuity tests: 20/70, notes: right eye; 20/50, notes: lest eye; 20/20, notes: right eye POD 1; 20/80; 20/25; 20/20. Therapeutic measures were taken as a result of uveitis.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the current available limited information in the case provided, the causal association between the event pan uveitis and the use of suspect product cannot be fully excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate